Session Details

S044 Resident Jeopardy

Sat, Mar 9, 1:00 PM - 4:00 PM
Room 23C
3 CME Available Symposium Residents
View Map

DESCRIPTION

Join your colleagues for self-assessment through this popular, fun and engaging game show format. Contestants representing various residency training programs will face Jeopardy-style queries and image based inquiries encompassing the breadth of dermatology in a friendly competition. Audience members are invited to play along and test their own knowledge. Which institution will emerge as the 2024 AAD Resident Jeopardy champion?

LEARNING OBJECTIVES

1.

Self-assess core competencies across numerous domains in dermatology.

2.

Identify gaps in medical knowledge.

3.

Interact and network with colleagues at similar career levels from various institutions across the country.

SCHEDULE

1:00 PM

AAD Resident Jeopardy

DIRECTOR

Lida Zheng, MD, FAAD

Lida Zheng, MD, FAAD

CO-DIRECTOR

Kassandra E Holzem, MD, FAAD

Kassandra E Holzem, MD, FAAD

SPEAKERS

Roger Ho, MD, FAAD

Roger Ho, MD, FAAD

Luke Samuel Johnson, MD, FAAD

Luke Samuel Johnson, MD, FAAD

Kiran Motaparthi, MD, FAAD

Kiran Motaparthi, MD, FAAD

Caitlin Peterman, MD, FAAD

Caitlin Peterman, MD, FAAD

Michelle B Tarbox, MD, FAAD

Michelle B Tarbox, MD, FAAD

DISCLOSURES

Roger Ho, MD, FAAD

Arcutis, Inc. – Advisory Board(Honoraria); EPI Health – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria);

Kassandra E Holzem, MD, FAAD

No financial relationships exist with ineligible companies.

Luke Samuel Johnson, MD, FAAD

Incyte Corporation – Other(Grants/Research Funding);

Kiran Motaparthi, MD, FAAD

Castle Biosciences, Inc – Consultant(Fees), Investigator(Grants/Research Funding); Proscia – Investigator(Grants/Research Funding);

Caitlin Peterman, MD, FAAD

No financial relationships exist with ineligible companies.

Michelle B Tarbox, MD, FAAD

Castle Biosciences – Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Sanofi/Regeneron – Investigator(Grants/Research Funding);

Lida Zheng, MD, FAAD

No financial relationships exist with ineligible companies.